Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis
NCT ID: NCT01119404
Last Updated: 2010-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2003-06-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hämeenlinna Metabolic Syndrome Research Program: Oxidized LDL and Arterial Elasticity in Metabolic Syndrome and Controls (HMS-01)
NCT01114763
Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes
NCT04093440
Effect of Exercise Training on the Function of the High Density Lipoprotein (HDL)-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Metabolic Syndrome(HERMET-Study)
NCT00515476
Effects of HIIT on Metabolic Syndrome
NCT04133129
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
NCT05117424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, we investigate calculated risk of the subjects (SCORE, FINRISK, Framingham score), platelet function and surrogate indicators for atherosclerosis like erectile dysfunction, plasma levels of oxidized LDL, arterial elasticity and biochemical markers for endothelial damage and dysfunction in different settings (case-only and case-control).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metabolic Syndrome
120 men with metabolic syndrome
No interventions assigned to this group
Coronary Heart Disease (CHD)
120 men with angiographically verified CHD
No interventions assigned to this group
Control
80 physically active men
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 120 Finnish men with metabolic syndrome (MetS) defined according to National Cholesterol Education Program (NCEP) Adult Treatment Panel III
* MetS diagnosed in routine health examination and laboratory tests
* Age: 30 to 65 years
Group 2: Coronary heart disease (CHD)
* 120 Finnish men with angiographically proven CHD
* Age: 30 to 65 years
Group 3: Control
* 80 Finnish men
* Exercising physically more than three times a week and more than 30 minutes per exercise on regular basis
* Never been studied or treated because of cardiovascular disease
* Age: 30 to 65 years
30 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Linnan Klinikka Oy
OTHER
Mehiläinen Hämeenlinna, Finland
UNKNOWN
Finnish Red Cross Blood Service
OTHER
Kanta-Häme Central Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Hospital of Kanta-Häme
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ari K Palomäki, MD PhD
Role: STUDY_DIRECTOR
Central Hospital of Kanta-Häme
Kalevi Oksanen, MD PhD
Role: STUDY_DIRECTOR
Central Hospital of Kanta-Häme
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Linnan Klinikka
Hämeenlinna, , Finland
Mehiläinen Hämeenlinna
Hämeenlinna, , Finland
Central Hospital of Kanta-Häme
Hämeenlinna, , Finland
Finnish Red Cross Blood Transfusion Service
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Saarinen HJ, Lahtela J, Mahonen P, Palomaki A; Hameenlinna Metabolic Syndrome Research Program Study Group. The association between inflammation, arterial stiffness, oxidized LDL and cardiovascular disease in Finnish men with metabolic syndrome - a 15-year follow-up study. BMC Cardiovasc Disord. 2024 Mar 15;24(1):162. doi: 10.1186/s12872-024-03818-x.
Pohjantahti-Maaroos H, Palomaki A, Kankkunen P, Husgafvel S, Knuth T, Vesterinen K, Oksanen K. Arterial elasticity and oxidized LDL among men with metabolic syndrome and different 10-year cardiovascular risk estimated by FINRISK and SCORE models. Ann Med. 2012 Aug;44(5):503-12. doi: 10.3109/07853890.2011.590520. Epub 2011 Jul 4.
Pohjantahti-Maaroos H, Palomaki A, Hartikainen J. Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis. BMC Cardiovasc Disord. 2011 Jun 27;11:36. doi: 10.1186/1471-2261-11-36.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMS-02
Identifier Type: OTHER
Identifier Source: secondary_id
KHMetS-02-AP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.